Loading...
XSTOIRLABa
Market cap51mUSD
Dec 23, Last price  
11.05SEK
1D
-0.45%
1Q
-9.80%
IPO
-81.19%
Name

IRLAB Therapeutics AB

Chart & Performance

D1W1MN
XSTO:IRLABa chart
P/E
—
P/S
100.79
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
5.91%
Rev. gr., 5y
216.07%
Revenues
6m
-90.71%
54,0002,880,000144,000109,00018,00026,000300,000207,782,00061,136,0005,678,000
Net income
-178m
L+55.72%
3,122,000-11,887,000-42,696,000-56,225,000-74,099,000-96,318,000-91,848,00051,781,000-114,203,000-177,839,000
CFO
-165m
L+15.59%
-11,024,000-27,655,000-40,818,000-57,741,000-70,790,000-91,201,000-89,214,000128,641,000-142,612,000-164,850,000
Earnings
Feb 14, 2025

Profile

IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
URL
https://irlab.se/
IPO date
Feb 28, 2017
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
5,678
-90.71%
61,136
-70.58%
207,782
69,160.67%
Cost of revenue
279,724
444,453
160,178
Unusual Expense (Income)
NOPBT
(274,046)
(383,317)
47,604
NOPBT Margin
22.91%
Operating Taxes
797
370
Tax Rate
0.78%
NOPAT
(274,046)
(384,114)
47,234
Net income
(177,839)
55.72%
(114,203)
-320.55%
51,781
-156.38%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,771
(360)
BB yield
-0.71%
0.02%
Debt
Debt current
2,940
3,595
3,034
Long-term debt
27,681
4,357
10,166
Deferred revenue
Other long-term liabilities
Net debt
(80,688)
(244,824)
(388,697)
Cash flow
Cash from operating activities
(164,850)
(142,612)
128,641
CAPEX
(293)
(3,376)
(708)
Cash from investing activities
(293)
(3,376)
(708)
Cash from financing activities
23,676
(3,134)
(3,045)
FCF
(272,709)
(383,775)
43,203
Balance
Cash
111,309
252,776
401,897
Long term investments
Excess cash
111,025
249,719
391,508
Stockholders' equity
(574,441)
(399,374)
(285,969)
Invested Capital
717,771
694,181
692,050
ROIC
6.84%
ROCE
11.72%
EV
Common stock shares outstanding
51,868
51,832
51,748
Price
7.50
-80.42%
38.30
-12.95%
44.00
4.76%
Market cap
389,013
-80.40%
1,985,162
-12.81%
2,276,930
13.71%
EV
308,325
1,740,338
1,888,233
EBITDA
(269,730)
(379,335)
51,078
EV/EBITDA
36.97
Interest
198
297
370
Interest/NOPBT
0.78%